Medical Xpress January 10, 2022
Biosimilar drugs could drive down prices for expensive medicines used to treat illnesses such as cancer and rheumatoid arthritis, with savings estimated to be $38.4 billion or 5.9% of projected total U.S. spending on biologics from 2021 to 2025, according to a new RAND Corporation study.
More aggressive biosimilar uptake and competition could trigger larger cuts, with savings estimated to be as large as $124.5 billion from 2021 to 2025 under the most-optimistic scenario.
The study estimates that most of the expected savings from biosimilars would be caused by downward pressure on the brand-name biologics they compete with, rather than lower biosimilar prices. The findings are published by the American Journal of Managed Care.
“Biosimilars have the potential to lower...